Designed Peptide Blocks Inflammation and Clotting Without Bleeding Risk

Current antithrombotic therapies, crucial for preventing conditions like stroke and heart attack, often increase the risk of bleeding, a major clinical challenge. Thromboinflammation, a complex interplay between coagulation and inflammation, is a key driver of various thrombotic disorders. This study addresses the critical need to develop antithrombotic agents that effectively prevent clots without compromising hemostasis or increasing bleeding risk.

The designed peptide demonstrated remarkable efficacy in inhibiting thromboinflammation. It significantly reduced thrombus formation, showing a 45% decrease in thrombus size and a 2.3-fold increase in the time to vessel occlusion compared to control groups. Crucially, and unlike conventional anticoagulants, the peptide did not significantly increase bleeding time or other bleeding parameters (p>0.05), effectively uncoupling antithrombotic action from hemorrhagic risk. Mechanistically, the peptide effectively blocked the IL-1β-FXIa axis, leading to a 60% reduction in FXIa (Factor XIa, a key coagulation enzyme) activity and a 30% decrease in circulating IL-1β (interleukin-1 beta, a pro-inflammatory cytokine) levels. The most significant finding was the peptide's ability to achieve potent antithrombosis, reducing clot burden by 45%, without any statistically significant increase in bleeding time (p>0.05), a critical advancement over existing therapies.